Competitive Technologies Booking Revenue From Worldwide Shipments of Pain Therapy...

Competitive Technologies Booking Revenue From Worldwide Shipments of Pain
Therapy Medical Devices

FAIRFIELD, Conn., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Competitive Technologies,
Inc. (NYSE Amex:CTT) announced today that it is moving forward with its plan to
restore profitability. Its Calmare Therapy Treatment*, pain therapy medical
device is treating patients in several locations worldwide. Revenue for product
shipments has been recorded for shipments made during the fiscal quarter ended
October 31, 2009.

The first shipment of 10 devices has been received by CTT's Switzerland-based
distributor, Life Episteme Group. This shipment will be followed by four
additional shipments of 10 devices each. In the U.S., Calmar Pain Relief, LLC,
of North Providence, RI, has received two devices at its offices in Rhode Island
in anticipation of the official opening of its pain therapy clinic on November
16, 2009. Four additional devices have been shipped to other organizations in
the U.S. and one device has also been shipped to Biogene Pharma, Ltd., CTT's
distributor in Bangladesh.

"Revenue is recorded based on shipments rather than orders from these devices
and has been booked in the first quarter of fiscal year 2010," according to John
B. Nano, CTT's Chairman, President and CEO. "We expect to see revenues from
sales of our Calmare Therapy Treatment grow throughout the fiscal year.

"Each of CTT's five directors has recently made an open market purchase of CTT
stock, which demonstrates confidence in CTT's performance. These stock purchases
and the above actions followed the 'going concern' statement describing our
financial condition that was included in our Form 10-K and auditors report,
filed October 27, 2009. Our plans to improve profitability were also included in
our Form 10-K, along with a summary of our $8 million equity financing agreement
with Fusion Capital Fund II, LLC."

CTT has exclusive worldwide rights to the Calmare Therapy Treatment device,
which was developed in Italy by CTT's client, Prof. Giuseppe Marineo. The
Calmare Therapy Treatment has been used to treat more than 3,000 patients in
Europe and the US. CTT partner, GEOMC Co., Ltd. of Korea, is producing the
device commercially for worldwide distribution. For more information about the
device, visit www.CalmareTT.com.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, provides distribution, patent and
technology transfer, sales and licensing services focused on the needs of its
customers and matching those requirements with commercially viable product or
technology solutions. CTT is a global leader in identifying, developing and
commercializing innovative products and technologies in life, electronic, nano,
and physical sciences developed by universities, companies and inventors. CTT
maximizes the value of intellectual assets for the benefit of its customers,
clients and shareholders. Visit CTT's website: www.competitivetech.net.

Statements made about our future expectations are forward-looking statements and
subject to risks and uncertainties as described in our most recent Annual Report
on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27,
2009, and other filings with the SEC, and are subject to change at any time. Our
actual results could differ materially from these forward-looking statements. We
undertake no obligation to update publicly any forward-looking statement.

* The Calmare Therapy Treatment uses Competitive Technologies' MC-5A pain
therapy medical device to provide rapid treatment of high-intensity oncologic
and neuropathic pain, including pain resistant to morphine and other narcotic
painkillers.

-0-
CONTACT: IR Services, LLC
Johnnie D. Johnson,
860 434 2465
jdjohnson@corpirservices.com